Key Highlights
• Strong Response in Induction Non-Responders: 37.2% of patients who did not respond during induction achieved clinical remission with continued obefazimod treatment.
• Dose Escalation Recaptures Remission: 45.5% of relapsed patients regained remission after their dose was escalated, highlighting flexible disease management.
• Favorable Long-Term Safety Profile: Malignancy rates in the Phase 3 data aligned with standard background levels seen in the broader UC population.
Shares of Abivax SA (NASDAQ: ABVX) surged approximately 38% following the release of encouraging long-term data from the ABTECT Maintenance Part 2 study, evaluating obefazimod, the company's oral once-daily candidate for moderately to severely active ulcerative colitis (UC). The data add to a growing body of evidence supporting obefazimod's potential utility even among historically difficult-to-treat patient subgroups.
Among the most notable findings, 37.2% of patients who did not initially respond during the induction phase of treatment ultimately achieved clinical remission after continuing on obefazimod through the maintenance period. This subgroup, often referred to as late or delayed responders, represents a clinically important population, as many UC therapies struggle to convert induction non-responders into remission over time.
Equally important, the study found that 45.5% of patients who experienced disease relapse during maintenance treatment were able to regain clinical remission following dose escalation. This finding suggests that obefazimod offers physicians a practical, flexible dosing strategy to recapture disease control in patients who lose response over time, a meaningful differentiator in a treatment landscape where relapse management remains a persistent clinical challenge.
On the safety side, Abivax reported that long-term Phase 3 data showed malignancy rates consistent with the expected background rate typically observed in the broader ulcerative colitis patient population. This finding is particularly significant given that safety monitoring, including for malignancy risk, has become an area of heightened scrutiny across the inflammatory bowel disease drug class following safety-related label updates for several competing oral therapies.
Taken together, the data strengthen the case for obefazimod's potential role in addressing refractory ulcerative colitis cases, specifically patients who fail to respond adequately to induction therapy or who relapse during long-term maintenance, two populations that represent significant unmet medical need within the UC treatment paradigm. The favorable risk profile, combined with demonstrated efficacy in difficult subgroups, may support a differentiated positioning for obefazimod relative to existing oral small-molecule and biologic alternatives.
The approximately 38% rally in Abivax shares reflects renewed investor confidence in obefazimod's commercial and regulatory prospects as the company advances toward potential regulatory submissions. With ulcerative colitis representing a multi-billion-dollar global therapeutic market, continued positive readouts from the ABTECT program could meaningfully de-risk obefazimod's path toward becoming a differentiated, best-in-class oral treatment option for patients across the disease severity spectrum.


_11_19_2026_08_23_11_186799.jpg)



Please wait processing your request...